Sanofi
corporate_fare Company Profile
Sanofi (NASDAQ:SNY) is a publicly traded company in the Life Sciences sector. Wiseek monitors SNY SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- FDA Approves Sanofi's Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes
- Sanofi Secures EU Approval for Sarclisa On-Body Injector, Halts Riliprubart Phase 3 Study
- Sanofi's Sarclisa Gets EU Nod for On-Body Injector, First Anticancer Treatment with Home Option
- FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease
- Sanofi's Efdoralprin Alfa Outperforms Standard Therapy in Phase 2 AATD Trial
Financial Snapshot
Insider Transactions
SNY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.